All In Biotech

Drug Trial Radar · NCT00021502

Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)

A Phase 3, Multi-Center, Randomized, Placebo Controlled Study of PHP When Administered by Continuous Infusion in Patients With Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)

Last checked: Nov 20, 2026Latest source record: Aug 14, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Actual

Start

Mar 2001

Primary completion

Aug 2003

Study completion May 2004

Sponsor

Lead sponsor
Apex BioscienceIndustry
Sponsor type
Industry
First posted
Jul 20, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the safety and effectiveness of pyridoxylated hemoglobin polyoxyethylene conjugate (PHP) administered by continuous intravenous (IV) infusion in systemic inflammatory response syndrome (SIRS) patients with shock. PHP is a human-derived chemically modified hemoglobin preparation. PHP selectively scavenges excess nitric oxide (NO) and does so in a catalytic, concentration-dependent reaction that results in the formation of the non-toxic NO metabolite, nitrate. PHP is postulated to reduce excess, toxic levels of NO while allowing critical beneficial levels of the molecule to persist.

Conditions

  • Shock
  • Systemic Inflammatory Response Syndrome

Interventions

  • pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.